Beam Therapeutics BEAM External General And Administrative Expenses — General And Administrative Expense

Other segment segments

Similar metrics at other companies

TRA

TRAXExternal Expenses — General And Administrative Expense

$8.72M+127%

ACHRG&A

$83.2M+106%

DNTHOther Costs — General And Administrative Expense

$2.65M+37.0%

LBRDKGeneral And Administrative Expense Including Stock Based Compensation

$5M-61.5%

FLUTU.S. — General and Administrative Expense

$133M+43.0%

JAN

JANCorporate And Other — General And Administrative Expense

$4.17M+134%

Questions, answered.

What is Beam Therapeutics's external general and administrative expenses — general and administrative expense?

Beam Therapeutics (BEAM) reported external general and administrative expenses — general and administrative expense of $13.37M in Q1 2026.

How has Beam Therapeutics's external general and administrative expenses — general and administrative expense changed year-over-year?

Beam Therapeutics's external general and administrative expenses — general and administrative expense increased by 148.8% year-over-year, from $5.37M to $13.37M.

What is the long-term trend for Beam Therapeutics's external general and administrative expenses — general and administrative expense?

Over 3 years (2022 to 2025), Beam Therapeutics's external general and administrative expenses — general and administrative expense has grown at a 3.0% compound annual growth rate (CAGR), from $25.89M to $28.32M.

What does external general and administrative expenses — general and administrative expense mean?

This metric represents the total operating costs incurred by the company to support its corporate infrastructure, including executive management, legal, finance, and human resources functions. It captures the overhead required to sustain business operations outside of direct research and development activities. Monitoring this expense helps investors evaluate the company's operational efficiency and the scalability of its administrative support structure as it advances its genetic medicine pipeline.